Trial Outcomes & Findings for Study of Low Level Laser Therapy to Reduce Body Circumference in Obese Individuals (NCT NCT01821352)

NCT ID: NCT01821352

Last Updated: 2015-12-11

Results Overview

Individual measurements in inches of the waist, hips and upper abdomen were combined to calculate a total body circumference measurement. Change in combined circumference measurement from baseline to 4 weeks was calculated for each subject. Individual subject success was defined as a change of 3.0 inches or more in the combined circumference measurement across the evaluation period. A decrease in combined circumference measurement is positive for individual subject success. An increase in combined circumference measurement is negative for individual subject success. Overall study success was defined as a 40% or greater difference between the proportion of individual successes in each treatment group.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

53 participants

Primary outcome timeframe

Baseline and 4 Weeks

Results posted on

2015-12-11

Participant Flow

Participant milestones

Participant milestones
Measure
Erchonia Obesity Laser
The Erchonia® Obesity Laser is made up of 10 independent 17 milliWatts (mW) 532 nanometer (nm) green laser diodes, each diode positioned 120 degrees apart from the next with each titled at a 30 degree angle. The Erchonia® Obesity Laser is a pulsed wave variable frequency device.
Placebo Laser
Placebo Laser device emits sham green light that has no therapeutic effect.
Overall Study
STARTED
28
25
Overall Study
COMPLETED
28
25
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Study of Low Level Laser Therapy to Reduce Body Circumference in Obese Individuals

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Erchonia Obesity Laser
n=28 Participants
The Erchonia® Obesity Laser is made up of 10 independent 17 milliWatts (mW), 532 nanometer (nm) green laser diodes, each diode positioned 120 degrees apart from the next with each titled at a 30 degree angle. The Erchonia® Obesity Laser is a pulsed wave variable frequency device.
Placebo Laser
n=25 Participants
Placebo Laser device emitting sham green light that has no therapeutic effect.
Total
n=53 Participants
Total of all reporting groups
Age, Continuous
46.32 years
STANDARD_DEVIATION 10.91 • n=5 Participants
47.84 years
STANDARD_DEVIATION 9.30 • n=7 Participants
47.04 years
STANDARD_DEVIATION 10.12 • n=5 Participants
Sex: Female, Male
Female
25 Participants
n=5 Participants
20 Participants
n=7 Participants
45 Participants
n=5 Participants
Sex: Female, Male
Male
3 Participants
n=5 Participants
5 Participants
n=7 Participants
8 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
4 Participants
n=5 Participants
6 Participants
n=7 Participants
10 Participants
n=5 Participants
Race (NIH/OMB)
White
23 Participants
n=5 Participants
19 Participants
n=7 Participants
42 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=5 Participants
0 Participants
n=7 Participants
1 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
28 participants
n=5 Participants
25 participants
n=7 Participants
53 participants
n=5 Participants
Total Circumference Measurement
123.35 inches
STANDARD_DEVIATION 10.29 • n=5 Participants
122.81 inches
STANDARD_DEVIATION 11.85 • n=7 Participants
123.04 inches
STANDARD_DEVIATION 10.95 • n=5 Participants
Body Mass Index (BMI)
34.58 kg/m2
STANDARD_DEVIATION 3.06 • n=5 Participants
33.60 kg/m2
STANDARD_DEVIATION 2.98 • n=7 Participants
34.04 kg/m2
STANDARD_DEVIATION 3.02 • n=5 Participants

PRIMARY outcome

Timeframe: Baseline and 4 Weeks

Individual measurements in inches of the waist, hips and upper abdomen were combined to calculate a total body circumference measurement. Change in combined circumference measurement from baseline to 4 weeks was calculated for each subject. Individual subject success was defined as a change of 3.0 inches or more in the combined circumference measurement across the evaluation period. A decrease in combined circumference measurement is positive for individual subject success. An increase in combined circumference measurement is negative for individual subject success. Overall study success was defined as a 40% or greater difference between the proportion of individual successes in each treatment group.

Outcome measures

Outcome measures
Measure
Erchonia Obesity Laser
n=28 Participants
The Erchonia® Obesity Laser is made up of 10 independent 17 milliWatts (mW), 532 nanometer (nm) green laser diodes, each diode positioned 120 degrees apart from the next with each titled at a 30 degree angle. The Erchonia® Obesity Laser is a pulsed wave variable frequency device.
Placebo Laser
n=25 Participants
Placebo Laser device emitting sham green light that has no therapeutic effect.
Difference in the Proportion of Primary Outcome Successes Between Treatment Groups for Change in Combined Circumference Measurements
20 participants
3 participants

PRIMARY outcome

Timeframe: Baseline and 4 Weeks

Individual measurements in inches of the waist, hips and upper abdomen were combined to calculate a total combined body circumference measurement. Change in combined circumference measurement is calculated as the difference in circumference measurements from baseline to endpoint (4 weeks). A negative (-) change indicates a decrease in circumference and is positive for study success. A positive (+) change indicates an increase in circumference and is negative for study success.

Outcome measures

Outcome measures
Measure
Erchonia Obesity Laser
n=28 Participants
The Erchonia® Obesity Laser is made up of 10 independent 17 milliWatts (mW), 532 nanometer (nm) green laser diodes, each diode positioned 120 degrees apart from the next with each titled at a 30 degree angle. The Erchonia® Obesity Laser is a pulsed wave variable frequency device.
Placebo Laser
n=25 Participants
Placebo Laser device emitting sham green light that has no therapeutic effect.
Change in Combined Circumference Measurement
-4.14 inches
Standard Deviation 2.99
-0.71 inches
Standard Deviation 1.26

OTHER_PRE_SPECIFIED outcome

Timeframe: 4 Weeks

Subjects rated satisfaction with the outcome of the study procedures with respect to change in body shape on the following 5-point scale: Very Satisfied, Somewhat Satisfied, Neither Satisfied nor Dissatisfied, Not Very Satisfied, Not at All Satisfied. Results are reported as the number of subjects in each treatment group who rated study outcome satisfaction as 'Very Satisfied' or 'Somewhat Satisfied'.

Outcome measures

Outcome measures
Measure
Erchonia Obesity Laser
n=28 Participants
The Erchonia® Obesity Laser is made up of 10 independent 17 milliWatts (mW), 532 nanometer (nm) green laser diodes, each diode positioned 120 degrees apart from the next with each titled at a 30 degree angle. The Erchonia® Obesity Laser is a pulsed wave variable frequency device.
Placebo Laser
n=25 Participants
Placebo Laser device emitting sham green light that has no therapeutic effect.
Subject Satisfaction With Procedure Outcome
22 participants
4 participants

Adverse Events

Erchonia Obesity Laser

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Placebo Laser

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Clinical Consultant

Regulatory Insight, Inc.

Phone: 615-712-9743

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place